Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide (Q85062314)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 19, 2010

Language	Label	Description	Also known as
English	Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide	scientific article published on September 19, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Mohamed Mursal

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Athina Zacharia

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Kathy Ciano

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Steven Khoo

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Alexander Stojadinovic

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Sathibalan Ponniah

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Jeremy D. Gates

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858449

17 July 2024

Guy T. Clifton

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858449

17 July 2024

Linda C. Benavides

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858449

17 July 2024

Alan K. Sears

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858449

17 July 2024

Mark G. Carmichael

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858449

17 July 2024

Matthew T. Hueman

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858449

17 July 2024

Jarrod P. Holmes

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858449

17 July 2024

Yusuf H. Jama

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858449

17 July 2024

George E. Peoples

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20858449

17 July 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20858449

17 July 2024

publication date

19 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

number of pages

7

1 reference

based on heuristic

inferred from page(s)

full work available at URL

https://api.elsevier.com/content/article/PII:S0264410X10013393?httpAccept=text/xml

1 reference

10.1016/J.VACCINE.2010.09.029

https://api.crossref.org/works/10.1016/J.VACCINE.2010.09.029

17 July 2024

https://api.elsevier.com/content/article/PII:S0264410X10013393?httpAccept=text/plain

1 reference

10.1016/J.VACCINE.2010.09.029

https://api.crossref.org/works/10.1016/J.VACCINE.2010.09.029

17 July 2024

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

28

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

47

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

7476-7482

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

The immunobiology of cancer immunosurveillance and immunoediting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Role of regulatory T cells and FOXP3 in human diseases.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

HER2/neu in the management of invasive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

HER2 and responsiveness of breast cancer to adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

The E75 HER2/neu peptide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

MHC class II allosteric site drugs: new immunotherapeutics for malignant, infectious and autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Editorial: Measurement of delayed skin-test responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

FOXP3 expression and overall survival in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Immunosuppressor T cells in tumor bearing host

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Control of regulatory T cell development by the transcription factor Foxp3

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Alterations in p53-specific T cells and other lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells and low-dose interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Dendritic cell vaccination induces tumor epitope-specific Th1 immune response in medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.09.029

7 January 2021

Cell interactions in the induction of tolerance: the role of thymic lymphocytes

3

1 reference

10.1016/J.VACCINE.2010.09.029

https://api.crossref.org/works/10.1016/J.VACCINE.2010.09.029

17 July 2024

HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer

11

1 reference

10.1016/J.VACCINE.2010.09.029

https://api.crossref.org/works/10.1016/J.VACCINE.2010.09.029

17 July 2024

Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine

33

1 reference

10.1016/J.VACCINE.2010.09.029

https://api.crossref.org/works/10.1016/J.VACCINE.2010.09.029

17 July 2024

Identifiers

10.1016/J.VACCINE.2010.09.029

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20858449%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q85062314&oldid=2229568272"